Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Kalaris is currently developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose study for neovascular Age-related Macular Degeneration (nAMD).

GlobeNewsWire • Aug 31, 2026

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the second quarter ended June 30, 2026 and provided business updates.

GlobeNewsWire • Aug 11, 2026

KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders

Abbott Cooper PLLC is investigating fiduciary duty claims for Kalaris Therapeutics (formerly AlloVir) holders who owned shares before November 7, 2024.

GlobeNewsWire • Aug 4, 2026

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study of TH103 in treatment naïve nAMD patients BERKELEY HEIGHTS, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Liisa Bayko, MBA, as Chief Financial Officer.

GlobeNewsWire • Jul 20, 2026

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts

GlobeNewsWire • Jul 17, 2026

Kalaris Appoints Laurie Keating to Board of Directors

Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth

GlobeNewsWire • Jul 6, 2026

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced an upcoming presentation of Phase 1a data at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting.

GlobeNewsWire • Jun 23, 2026

Kalaris to Present at Clinical Trials at the Summit 2026

BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose results from treatment-naïve patients with Neovascular Age-Related Macular Degeneration (AMD) — one of the leading causes of vision loss worldwide. These data were recently presented at Retina World Congress 2026.

GlobeNewsWire • Jun 12, 2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials remain on track for 2027 year-end initiation $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the first quarter ended March 31, 2026 and provided business updates.

GlobeNewsWire • May 12, 2026

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027

GlobeNewsWire • Mar 17, 2026